Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.352 Factor de Impacto de 5 años: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

Comprar Publicación $153.00 Volumen 27, 2007 Edición 5

DOI: 10.1615/CritRevImmunol.v27.i5

Tabla de Contenidos:

PART IV. Cytokine and Hormone Immunotherapy
Treatment of AIDS-Related Kaposi's Sarcoma with Interleukin-12: Rationale and Preliminary Evidence of Clinical Activity

Robert Yarchoan, James M. Pluda, Kathleen M. Wyvill, Karen Aleman, Isaac R. Rodriguez-Chavez, Giovanna Tosato, Andrew T. Catanzaro, Seth M. Steinberg, Richard F. Little
pages 401-414
DOI: 10.1615/CritRevImmunol.v27.i5.10
Targeting OX40 and OX40L for the Treatment of Autoimmunity and Cancer
William L. Redmond, Andrew D. Weinberg
pages 415-436
DOI: 10.1615/CritRevImmunol.v27.i5.20
Gene Expression Signatures of Interleukin-2 In Vivo and In Vitro and Their Relation to Anticancer Therapy
Ping Jin, Ena Wang, Maurizio Provenzano, David Stroncek, Francesco M. Marincola
pages 437-448
DOI: 10.1615/CritRevImmunol.v27.i5.30
PART V. Modulation of Antitumor Vaccine Strategies
Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy

Philip M. Arlen, James L. Gulley, Ravi A. Madan, James W. Hodge, Jeffrey Schlom
pages 451-462
DOI: 10.1615/CritRevImmunol.v27.i5.40
Immunogenicity of Dendritic-Tumor Fusion Hybrids and Their Utility in Cancer Immunotherapy
Suyu Shu, Rongxiu Zheng, Walter T. Lee, Peter A. Cohen
pages 463-483
DOI: 10.1615/CritRevImmunol.v27.i5.50
Improving Immunotherapy by Conditionally Enhancing MHC Class I Presentation of Tumor Antigen-Derived Peptide Epitopes
Walter J. Storkus, Christopher Herrem, Mayumi Kawabe, Peter A. Cohen, Ronald M. Bukowski, James H. Finke, Amy K. Wesa
pages 485-493
DOI: 10.1615/CritRevImmunol.v27.i5.60

Critical Reviews™ in Immunology

Model for the recruitment of inducer-specific TNF-α gene enhanceosome in T lymphocytes., Vol. 29, Iss.2, Viral Mechanisms Involved in the TranscriptionalCBP/p300 Regulation of Inflammat..... Model for the recruitment of inducer-specific TNF-α gene enhanceosome in T lymphocytes., Vol. 29, Iss.2, Viral Mechanisms Involved in the TranscriptionalCBP/p300 Regulation of Inflammat..... Viral Mechanisms Involved in the Transcriptional CBP/р300 Regulation of Inflammatory and Immune Responses
Activation of several B cells is necessary for exosome release.Vol. 29, Iss. 3, Exosome Release by Primary B Cells. Activation of several B cells is necessary for exosome release.Vol. 29, Iss. 3, Exosome Release by Primary B Cells. Exosome Release by Primary B Cells
Homology model of human GrM. Vol. 29, Iss. 4, The Biology of Granzyme M: A Serine Protease with Unique Features. Homology model of human GrM. Vol. 29, Iss. 4, The Biology of Granzyme M: A Serine Protease with Unique Features. Biology of Granzyme M: A Serine Protease with Unique Features
(A) Gap-junction formation, (B) A three-dimensional collagen matrix Vol. 30, Iss. 6, Endothelial Cells as Key Determinants of the Tumor Microenvironment. (A) Gap-junction formation, (B) A three-dimensional collagen matrix Vol. 30, Iss. 6, Endothelial Cells as Key Determinants of the Tumor Microenvironment. Endothelial Cells as Key Determinants of the Tumor Microenvironment: Interaction with Tumor Cells, Extracellular Matrix and Immune Killer Cells
Biphasic HCV RNA decline after IFN treatment of chronic hepatitis C. Vol. 30, Iss. 2, Treatment of Hepatitis C Virus Infection with Interferon and Small Molecule Direct Antivirals. Biphasic HCV RNA decline after IFN treatment of chronic hepatitis C. Vol. 30,  Iss. 2, Treatment of Hepatitis C Virus Infection with Interferon and Small Molecule Direct Antivirals. Treatment of Hepatitis C Virus Infection With Interferon and Small Molecule Direct Antivirals: Viral Kinetics and Modeling